A Revolution in Women's Health: The Scalpel-Free Future of Permanent Birth Control Arrives

Femasys has secured historic European approval for FemBloc, the world's first non-surgical permanent birth control.
The revolutionary in-office procedure eliminates the need for surgery, anesthesia, and the risks of traditional sterilization.
This landmark approval signals a paradigm shift in women's health, offering a safer, more accessible choice for reproductive freedom.

For centuries, the path to permanent birth control for women involved a scalpel. That era is ending. Femasys Inc. (Nasdaq: FEMY) has just announced a monumental victory: the first-ever global regulatory approval for FemBloc®, a groundbreaking permanent birth control that requires no surgery, no incisions, and no general anesthesia^{1, 2}.

This historic Conformité Européene (CE) mark certification ushers in a new age of choice, leaving behind the inherent risks of infection, bleeding, and surgical complications tied to traditional methods⁵. The FemBloc system is a triumph of modern science: a simple, in-office procedure where a proprietary blended polymer is delivered into the fallopian tubes, prompting the body to create a natural, permanent barrier^{1, 4}.

"European approval of the entire FemBloc System represents a major milestone for Femasys and the field of women's health," stated Kathy Lee-Sepsick, Femasys’ CEO and Founder, celebrating the rigorous scientific validation of their technology¹.

With commercialization beginning in Spain, Femasys is not just introducing a product; it’s spearheading a global movement. As the company continues its pivotal trials for U.S. approval, women across Europe now have access to a future of permanent contraception that is finally safer, more accessible, and profoundly empowering^{1, 6}.

Learn more at www.femasys.com, or follow us on X, LinkedIn, and Facebook.

A Revolution in Women's Health: The Scalpel-Free Future of Permanent Birth Control Arrives

References

Stay Updated!